PETA Science Consortium International and MatTek Life Sciences 3D Reconstructed Human Respiratory Tissue Award

In May 2021, PETA Science Consortium International e.V. and MatTek Life Sciences awarded free three-dimensional reconstructed human tissue models for testing the respiratory effects of inhaled substances.

MatTek offers a variety of human cell–based tissues that are used for regulatory safety testing, product development, and basic research applications. This award specifically applied to the EpiAlveolar™ and EpiAirway™ tissues that can be used to test the effects of inhaled chemicals, drugs, nanomaterials, and pathogens. EpiAlveolar models the lower respiratory tract and includes primary human alveolar epithelial cells, pulmonary endothelial cells, and fibroblasts, while EpiAirway models the upper respiratory tract and comprises normal, human-derived tracheal/bronchial epithelial cells.

We are pleased to announce the winners:

First Place

Dr Eleonore Fröhlich

Professor Dr Eleonore Fröhlich from the Medical University of Graz in Austria will receive US$10,000, redeemable for EpiAlveolar™ and EpiAirway™ tissues. She plans to use the tissues to evaluate the effects of different sizes of carbon nanotubes on the function of the upper airways (e.g. mucociliary clearance and ciliary beating frequency) and lower airways (e.g. morphology and cytokine secretion).

“I am so happy that I won this award! The use of EpiAirway and EpiAlveolar in parallel will enable us to compare the effects of various carbon nanotubes on functional aspects of the upper and lower airways.” — Dr Fröhlich






Dr Elizabeth Fiona McInnes

Dr Elizabeth Fiona McInnes from Syngenta Ltd UK will receive US$5,000, redeemable for EpiAlveolar™ and EpiAirway™ tissues that she will use to assess the potential toxicity of agrochemicals in the upper and lower respiratory tract.

“Syngenta Ltd are delighted to have been chosen as runner-up for this award. We plan to use the MatTek EpiAlveolar and EpiAirway tissues to generate data on potential pesticide respiratory toxicity to convince regulatory agencies that an in vivo inhalation study in the rodent model is not necessary.” — Dr McInnes